What's New

Last Posted: Jul 16, 2023

• Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas
  S Reynolds, NCI Blog, July 2023
• Machine Learning Logistic Regression Model for Early Decision Making in Referral of Children with Cervical Lymphadenopathy Suspected of Lymphoma.
  Eline A M Zijtregtop et al. Cancers 2023 15(4)
• An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study.
  Torrente María et al. Cancers 2022 14(16)
• Peripheral blood DNA methylation profiles predict future development of B-cell Non-Hodgkin Lymphoma
  AE Perez et al, NPJ Precision Oncology, July 21, 2022
• High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.
  Ferrari Anna et al. Leukemia & lymphoma 2022 1-7
• Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases.
  Chen Chunni et al. Diagnostic pathology 2021 16(1) 114
• An overview of genetic predisposition to familial hematological malignancies.
  Hamadou Walid Sabri et al. Bulletin du cancer 2021
• New biomarkers in non-Hodgkin lymphoma and acute leukemias.
  Rubio-Jurado Benjamín et al. Advances in clinical chemistry 2020 9619-53
• The application of antigen receptor gene rearrangement of BIOMED-2 in the pathologic diagnosis of 348 cases with non-Hodgkin lymphoma in a single institution in Southwest of China.
  Liu Xueni et al. Pathology, research and practice 2019 Nov 215(11) 152615
• Clinical application of thiopurine pharmacogenomics in pediatrics.
  Pavlovic Sonja et al. Current drug metabolism 2020 Mar
• Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
  Crombie Jennifer L et al. Surgical oncology clinics of North America 2020 Jan 29(1) 115-125
• CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries
  ASCO Post, August 8, 2019
• Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non-Hodgkin Lymphoma.
  Wang Zhaoming et al. JAMA oncology 2019 Jul
• The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment.
  Wong Doo Nicole et al. Cancers 2019 Jul 11(7)
• Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.
  Shin Seung-Ho et al. Leukemia & lymphoma 2019 Feb 1-10
• Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
  Galanina Natalie et al. Cancers 2018 Dec 11(1)
• Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
  Wu Fang-Tian et al. Annals of hematology 2018 Oct
• Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome.
  Samadder N Jewel et al. JAMA oncology 2017 Aug
• Family history of venous thromboembolism and risk of hospitalized thromboembolism in cancer patients: A nationwide family study.
  Zöller Bengt et al. Thrombosis research 2015 Sep 136(3) 573-81
• Familial Risk in Patients With Carcinoma of Unknown Primary.
  Samadder N Jewel et al. JAMA oncology 2015 Dec 1-7

More